Poster presentation to reveal data regarding in vivo efficacy against patient-derived xenografts (PDX) models of T-cell acute lymphoblastic leukemia (T-ALL)
Taipei, Taiwan, October 24, 2017 — OBI Pharma, Inc., a Taiwan biopharma company (TPEx: 4174), announced that new data, for OBI-3424 in vivo efficacy against patient-derived xenograft (PDX) models of T-cell acute lymphoblastic leukemia (T-ALL), will be presented at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics in Philadelphia, Pennsylvania, USA, by Professor Richard B. Lock, PhD, Head of the Children’s Cancer Institute’s Leukemia Biology Program at the Lowy Cancer Research Centre in Sydney, Australia. The study was supported by National Cancer Institute (NCI) grants CA199222 & CA199000, and conducted by the NCI Pediatric Preclinical Testing Consortium.
Poster presentation time: Sunday, October 29, 2017, 12:30 p.m. – 3:00 p.m. EDT
Title: The AKR1C3-Activated Prodrug OBI-3424 Exerts Profound In Vivo Efficacy Against Preclinical Models of T-Cell Acute Lymphoblastic Leukemia (T-ALL); a Pediatric Preclinical Testing Consortium Study
Session Title: Late Breaking Poster Session B
Abstract number: LB-B16
Presenting author: Prof. Richard B. Lock, PhD, Head of the Children’s Cancer Institute, Leukemia Biology Program, at the Lowy Cancer Research Centre, (Sydney, Australia)
Location: Pennsylvania Convention Center, Hall E. Philadelphia, Pennsylvania, USA.
OBI-3424 is a first-in-class novel small-molecule prodrug that selectively targets cancers that overexpress the enzyme aldo-keto reductase 1c3 (AKR1C3), and selectively releases a potent DNA alkylating agent in the presence of the AKR1C3 enzyme.
AKR1C3 overexpression has been documented in a number of treatment-resistant and difficult to treat cancers including: hcastrate-resistant prostate cancer (CRPC) and T-cell acute lymphoblastic leukemia (T-ALL).
Furthermore, individualized patient selection by staining for AKR1C3 overexpression by immunohistochemistry can be performed to identify patients with other tumor types most likely to respond to treatment with OBI-3424, offering the possibility for a streamlined clinical development strategy.
OBI Pharma plans an Investigational New Drug (IND) application filing with the U.S. Food and Drug Administration (FDA) in early 2018.
OBI Pharma has OBI-3424 worldwide rights with the exception of the following countries, of which Ascenta Pharma has rights: China, Hong Kong, Macao, Taiwan, Japan, South Korea, Singapore, Malaysia, Thailand, Turkey and India.
About OBI Pharma
OBI Pharma, Inc. is a Taiwan biopharmaceutical company that was established in 2002. Its mission is to develop and license novel therapeutic agents for unmet medical needs against cancer targets such as Globo series, AKR1C3, and other promising targets. The company’s flagship product is Adagloxad Simolenin (formerly OBI-822), a first-in-class active immunotherapy for metastatic breast cancer. OBI is also developing next generation immunotherapies for difficult to treat cancers, including lung, colorectal, pancreatic, gastric, and ovarian cancer. Additional information can be found at www.obipharma.com.
Statements included in this press release that are not a description of historical facts are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements include, but are not limited to, statements about future clinical trials, results, and the timing of such trials and results. Such risk factors are identified and discussed from time to time in OBI Pharma’s reports and presentations, including OBI Pharma’s filings with the Taiwan Securities and Futures Bureau.
OBI Pharma, Inc.
+886 (2) 2786-6589